Stanford, CA, United States of America

Jack Leider Sloane


Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jack Leider Sloane: Innovator in Bryostatin Compounds

Introduction

Jack Leider Sloane is a prominent inventor based in Stanford, California. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of bryostatin compounds. With a total of three patents to his name, Sloane's work focuses on innovative methods for synthesizing these compounds, which have potential therapeutic applications.

Latest Patents

Sloane's latest patents include groundbreaking methods for preparing a variety of bryostatin compounds. One of his notable patents details methods for preparing bryostatin 1 in multi-gram quantities using a low and unprecedented number of convergent synthetic steps from commercially available materials. These methods are scalable and designed to meet clinical needs with low estimated material costs. Additionally, he has developed prodrug derivatives of protein kinase C (PKC) modulators. These prodrugs exhibit efficacy with low toxicity levels and improved stability, making them valuable for academic research and potential therapeutic use.

Career Highlights

Sloane is affiliated with Leland Stanford Junior University, where he conducts his research and development work. His innovative approaches to synthesizing bryostatin compounds have positioned him as a key figure in the field of medicinal chemistry. His contributions are not only significant in terms of scientific advancement but also in their potential impact on clinical applications.

Collaborations

Some of Sloane's notable coworkers include Paul A. Wender and Ryan Quiroz. Their collaborative efforts have further enhanced the research and development of bryostatin compounds and related therapeutic agents.

Conclusion

Jack Leider Sloane's work in the field of bryostatin compounds exemplifies the intersection of innovation and practical application in pharmaceutical research. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…